Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
44.22
-0.04 (-0.09%)
Apr 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 43.83 - 44.61
52 week 32.18 - 44.78
Open 44.12
Vol / Avg. 8.99M/6.69M
Mkt cap 24.35B
P/E 7.27
Div/yield 0.12/1.04
EPS 6.08
Shares 550.17M
Beta 0.64
Inst. own 85%
Jul 27, 2016
Q2 2016 Baxter International Inc Earnings Release (Estimated) Add to calendar
May 10, 2016
Baxter International Inc at Bank of America Merrill Lynch Health Care Conference - 8:00PM EDT - Add to calendar
May 9, 2016
Baxter International Inc Investor Conference - 1:00PM EDT - Add to calendar
May 4, 2016
Baxter International Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 3, 2016
Baxter International Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Apr 26, 2016
Q1 2016 Baxter International Inc Earnings Call - Webcast
Apr 26, 2016
Q1 2016 Baxter International Inc Earnings Release
Mar 15, 2016
Baxter International Inc at Barclays Global Healthcare Conference
Mar 9, 2016
Baxter International Inc at Cowen Health Care Conference
Feb 24, 2016
Baxter International Inc at RBC Capital Markets Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 142.61% 3.94%
Operating margin 7.92% 5.58%
EBITD margin - 14.79%
Return on average assets - 1.68%
Return on average equity - 4.63%
Employees 50,000 -
CDP Score - 99 B

Address

One Baxter Pkwy, Df2-1W
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Officers and directors

Jose E. Almeida Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
James K. Saccaro Corporate Vice President and Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Marcus Schabacker M.D. Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
.. Karp Corporate Vice President, Controller
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Brik V. Eyre Corporate Vice President, President - Hospital Products
Age: 52
Bio & Compensation  - Reuters
Robert Felicelli Corporate Vice President - Quality
Age: 57
Bio & Compensation  - Reuters
Timothy P. Lawrence Corporate Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jill M. Schaaf Corporate Vice President and President - Renal
Age: 52
Bio & Compensation  - Reuters